hNPC01
Phase 1Small molecule
hNPC01 is one of 38 small molecule programs targeting Ischemic stroke. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
116 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Atorvastatin Calcium
Merck & Co.Phase 3
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
PCSK9 Inhibitor
YYun Dai Chen
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
Tenecteplase or Alteplase
IInsel Gruppe AG, University Hospital Bern
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hNPC01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- HHopstem Biotechnology Inc.